Review article · 2025 · Open access
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Journal of Hematology & Oncology, 18(1), 45 · Published 17 April 2025 · DOI 10.1186/s13045-025-01692-4
In brief
“Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy” is a 2025 review article by Naimeng Liu and 7 co-authors, published in Journal of Hematology & Oncology. OpenAlex counts 55 citations as of 21 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Journal of Hematology & Oncology.
- Citations
- 55
- Most cited in
- 2026 (39)
- Field-weighted impact
- 3.62
- References
- 279
- Authors
- 8
Abstract
In situ vaccination (ISV) has emerged as a promising strategy in cancer immunotherapy, offering a targeted approach that uses the tumor microenvironment (TME) to stimulate an immune response directly at the tumor site. This method minimizes systemic exposure while maintaining therapeutic efficacy and enhancing safety. Recent advances in nanotechnology have enabled new approaches to ISV by utilizing nanomaterials with unique properties, including enhanced permeability, retention, and controlled drug release. ISV employing nanomaterials can induce immunogenic cell death and reverse the immunosuppressive and hypoxic TME, thereby converting a "cold" tumor into a "hot" tumor and facilitating a more robust immune response. This review examines the mechanisms through which nanomaterials-based ISV enhances anti-tumor immunity, summarizes clinical applications of these strategies, and evaluates its capacity to serve as a neoadjuvant therapy for eliminating micrometastases in early-stage cancer patients. Challenges associated with the clinical translation of nanomaterials-based ISV, including nanomaterial metabolism, optimization of treatment protocols, and integration with other therapies such as radiotherapy, chemotherapy, and photothermal therapy, are also discussed. Advances in nanotechnology and immunotherapy continue to expand the possible applications of ISV, potentially leading to improved outcomes across a broad range of cancer types.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Liu, N., Wang, X., Wang, Z., Yonemori, K., Fang, Y., Gao, J., Kong, X., & Wang, J. (2025). Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy. Journal of Hematology & Oncology, 18(1), 45. https://doi.org/10.1186/s13045-025-01692-4
MLA 9
Liu, Naimeng, et al. “Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy.” Journal of Hematology & Oncology, vol. 18, no. 1, 2025, p. 45. https://doi.org/10.1186/s13045-025-01692-4.
Chicago
Liu, Naimeng, Xiangyu Wang, Zhongzhao Wang, Kan Yonemori, Yi Fang, Jidong Gao, Xiangyi Kong, and Jing Wang. 2025. “Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy.” Journal of Hematology & Oncology 18 (1): 45. https://doi.org/10.1186/s13045-025-01692-4.
Harvard
Liu, N. et al. (2025) ‘Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy’, Journal of Hematology & Oncology, 18(1), p. 45. doi:10.1186/s13045-025-01692-4.
IEEE
N. Liu et al., “Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy,” Journal of Hematology & Oncology, vol. 18, no. 1, p. 45, 2025, doi: 10.1186/s13045-025-01692-4.
BibTeX
@article{liu2025nanomaterials,
title = {{Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy}},
author = {Liu, Naimeng and Wang, Xiangyu and Wang, Zhongzhao and Yonemori, Kan and Fang, Yi and Gao, Jidong and Kong, Xiangyi and Wang, Jing},
journal = {Journal of Hematology \& Oncology},
year = {2025},
volume = {18},
number = {1},
pages = {45},
doi = {10.1186/s13045-025-01692-4},
url = {https://doi.org/10.1186/s13045-025-01692-4}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- in situ vaccination
- nanomaterials
- cancer immunotherapy
- tumor microenvironment
- immunogenic cell death
- cold tumor conversion
- enhanced permeability and retention effect
- controlled drug release
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Liu, N., Wang, X., Wang, Z., Yonemori, K., Fang, Y., Gao, J., Kong, X., & Wang, J. (2025). Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy. Journal of Hematology & Oncology, 18(1), 45. https://doi.org/10.1186/s13045-025-01692-4
How many times has this paper been cited?
55 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Hematology & Oncology: sign in and open the PDF from this page.
Who wrote this paper?
Naimeng Liu, Xiangyu Wang, Zhongzhao Wang, Kan Yonemori, Yi Fang, Jidong Gao, Xiangyi Kong, Jing Wang.
What is the DOI of this paper?
10.1186/s13045-025-01692-4, permanently at https://doi.org/10.1186/s13045-025-01692-4. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.